Market Closed -
Nasdaq Helsinki
11:29:53 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
35.85
EUR
|
+1.30%
|
|
+10.65%
|
-8.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,786
|
5,267
|
5,119
|
7,179
|
5,509
|
5,044
|
-
|
-
|
Enterprise Value (EV)
1 |
5,647
|
5,081
|
5,010
|
7,060
|
5,603
|
5,048
|
5,038
|
5,081
|
P/E ratio
|
28.9
x
|
24.1
x
|
26.5
x
|
20.6
x
|
25.5
x
|
19.8
x
|
20.2
x
|
15.6
x
|
Yield
|
3.63%
|
4%
|
4.11%
|
3.12%
|
4.13%
|
4.6%
|
4.77%
|
4.95%
|
Capitalization / Revenue
|
5.51
x
|
4.89
x
|
4.92
x
|
5.36
x
|
4.63
x
|
3.73
x
|
3.49
x
|
3.22
x
|
EV / Revenue
|
5.37
x
|
4.71
x
|
4.81
x
|
5.27
x
|
4.71
x
|
3.73
x
|
3.48
x
|
3.25
x
|
EV / EBITDA
|
18.3
x
|
15.1
x
|
17.3
x
|
14.5
x
|
17.2
x
|
14.6
x
|
13.4
x
|
12.2
x
|
EV / FCF
|
24.7
x
|
20.3
x
|
38.5
x
|
21.7
x
|
105
x
|
23.9
x
|
25.9
x
|
21.4
x
|
FCF Yield
|
4.04%
|
4.93%
|
2.6%
|
4.6%
|
0.95%
|
4.18%
|
3.87%
|
4.68%
|
Price to Book
|
7.44
x
|
7.2
x
|
6.86
x
|
7.91
x
|
6.19
x
|
5.44
x
|
5.49
x
|
5
x
|
Nbr of stocks (in thousands)
|
140,492
|
140,463
|
140,563
|
140,202
|
140,351
|
140,501
|
-
|
-
|
Reference price
2 |
41.27
|
37.53
|
36.52
|
51.24
|
39.27
|
35.85
|
35.85
|
35.85
|
Announcement Date
|
2/5/20
|
2/9/21
|
2/10/22
|
2/9/23
|
2/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,051
|
1,078
|
1,041
|
1,341
|
1,190
|
1,354
|
1,447
|
1,565
|
EBITDA
1 |
308.9
|
336.5
|
289.1
|
487.1
|
326.4
|
346.4
|
375.9
|
416.6
|
EBIT
1 |
252.8
|
280.1
|
243.3
|
439.6
|
274.9
|
291.7
|
309.6
|
366
|
Operating Margin
|
24.05%
|
25.98%
|
23.37%
|
32.79%
|
23.11%
|
21.55%
|
21.4%
|
23.39%
|
Earnings before Tax (EBT)
1 |
250.8
|
278.3
|
242.3
|
440.3
|
271.9
|
319.8
|
313.5
|
407.1
|
Net income
1 |
200.4
|
219.9
|
193.8
|
349.5
|
216.8
|
254.3
|
249.2
|
323.7
|
Net margin
|
19.07%
|
20.4%
|
18.62%
|
26.07%
|
18.22%
|
18.79%
|
17.23%
|
20.69%
|
EPS
2 |
1.430
|
1.560
|
1.380
|
2.490
|
1.540
|
1.811
|
1.774
|
2.299
|
Free Cash Flow
1 |
228.2
|
250.6
|
130.3
|
324.8
|
53.4
|
210.8
|
194.8
|
237.9
|
FCF margin
|
21.71%
|
23.24%
|
12.52%
|
24.23%
|
4.49%
|
15.57%
|
13.46%
|
15.2%
|
FCF Conversion (EBITDA)
|
73.88%
|
74.47%
|
45.07%
|
66.68%
|
16.36%
|
60.85%
|
51.82%
|
57.11%
|
FCF Conversion (Net income)
|
113.87%
|
113.96%
|
67.23%
|
92.93%
|
24.63%
|
82.9%
|
78.16%
|
73.49%
|
Dividend per Share
2 |
1.500
|
1.500
|
1.500
|
1.600
|
1.620
|
1.650
|
1.710
|
1.773
|
Announcement Date
|
2/5/20
|
2/9/21
|
2/10/22
|
2/9/23
|
2/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
276.5
|
270.6
|
283.7
|
491.8
|
294.5
|
277.9
|
289.6
|
301.1
|
321.1
|
308.5
|
313.5
|
333.3
|
399.9
|
EBITDA
1 |
52.6
|
83
|
93.6
|
257.4
|
53.2
|
67.7
|
59.2
|
93.5
|
106
|
68.5
|
74.4
|
73.3
|
133
|
EBIT
1 |
39.9
|
71.5
|
82
|
245.4
|
40.7
|
55.5
|
46.5
|
80
|
92.9
|
56
|
62.99
|
68.52
|
100.4
|
Operating Margin
|
14.43%
|
26.42%
|
28.9%
|
49.9%
|
13.82%
|
19.97%
|
16.06%
|
26.57%
|
28.93%
|
18.15%
|
20.09%
|
20.56%
|
25.12%
|
Earnings before Tax (EBT)
1 |
39.8
|
72.1
|
83.1
|
244.6
|
40.5
|
55.1
|
45.8
|
78.5
|
92.4
|
54.9
|
57.45
|
66
|
120
|
Net income
1 |
32.8
|
57.3
|
66.1
|
194.5
|
31.7
|
43.8
|
36.4
|
61.4
|
75.1
|
43.8
|
45.7
|
52.6
|
94.9
|
Net margin
|
11.86%
|
21.18%
|
23.3%
|
39.55%
|
10.76%
|
15.76%
|
12.57%
|
20.39%
|
23.39%
|
14.2%
|
14.58%
|
15.78%
|
23.73%
|
EPS
2 |
0.2300
|
0.4100
|
0.4700
|
1.380
|
0.2300
|
0.3100
|
0.2600
|
0.4400
|
0.5400
|
0.3100
|
0.3333
|
0.2667
|
0.5400
|
Dividend per Share
|
1.500
|
-
|
-
|
-
|
1.600
|
-
|
-
|
-
|
1.620
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
4/28/22
|
7/15/22
|
10/20/22
|
2/9/23
|
4/27/23
|
7/17/23
|
10/26/23
|
2/13/24
|
4/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
93.3
|
4.12
|
-
|
37
|
Net Cash position
1 |
139
|
186
|
108
|
119
|
-
|
-
|
5.15
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.2858
x
|
0.0119
x
|
-
|
0.0888
x
|
Free Cash Flow
1 |
228
|
251
|
130
|
325
|
53.4
|
211
|
195
|
238
|
ROE (net income / shareholders' equity)
|
25.8%
|
29.1%
|
26.2%
|
42.2%
|
24.1%
|
28.1%
|
26.8%
|
35.5%
|
ROA (Net income/ Total Assets)
|
18.4%
|
29.1%
|
17.4%
|
26.7%
|
14.7%
|
14.4%
|
13.9%
|
15.6%
|
Assets
1 |
1,091
|
755.4
|
1,115
|
1,309
|
1,471
|
1,761
|
1,796
|
2,077
|
Book Value Per Share
2 |
5.550
|
5.210
|
5.320
|
6.480
|
6.340
|
6.590
|
6.530
|
7.170
|
Cash Flow per Share
2 |
1.930
|
2.130
|
1.540
|
3.090
|
0.8500
|
2.230
|
2.000
|
2.800
|
Capex
1 |
42.6
|
48.5
|
85.4
|
73.1
|
117
|
80.9
|
79.1
|
88.5
|
Capex / Sales
|
4.05%
|
4.5%
|
8.2%
|
5.45%
|
9.82%
|
5.98%
|
5.46%
|
5.66%
|
Announcement Date
|
2/5/20
|
2/9/21
|
2/10/22
|
2/9/23
|
2/13/24
|
-
|
-
|
-
|
Last Close Price
35.85
EUR Average target price
39.2
EUR Spread / Average Target +9.34% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.71% | 5.33B | | +25.83% | 653B | | +27.00% | 556B | | -6.76% | 354B | | +20.34% | 331B | | +3.00% | 296B | | +13.09% | 233B | | +5.46% | 201B | | -9.61% | 193B | | -6.26% | 144B |
Other Pharmaceuticals
|